Holen Sie sich die Stockscreener-App
22.40
4.23%
-0.99
Vorhandelsmarkt:
22.52
0.12
+0.54%
Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten
Acadia Pharmaceuticals appoints Jonathan M. Poole to board of directors By Investing.com - Investing.com Canada
Acadia Pharmaceuticals appoints Jonathan M. Poole to board of directors - Investing.com Nigeria
Acadia Pharmaceuticals Appoints Jonathan Poole to Board, Audit Committee - TipRanks
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Revised) - Finviz
ACADIA Pharmaceuticals Inc. $ACAD Stock Position Raised by Fisher Asset Management LLC - MarketBeat
Acadia Faces EU Setback On Trofinetide As Valuation Signals Diverge - Yahoo Finance
Is It Time To Revisit ACADIA Pharmaceuticals (ACAD) After Recent Share Price Weakness? - Yahoo Finance
JP Morgan Raises Price Target for ACADIA Pharmaceuticals (ACAD) to $34 | ACAD Stock News - GuruFocus
ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
CHMP Setback Puts Acadia Rett Plans And Revenue Outlook In Focus - simplywall.st
ACAD Announces New Review Following CHMP’s Decision Against Rett Syndrome Medication in Europe - Bitget
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU - Finviz
Rafferty Asset Management LLC Boosts Stock Position in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors - BioSpace
ACADIA (ACAD) -7.1%: EU Agency Rejects Rett Syndrome Drug - Trefis
Acadia Pharmaceuticals appoints Jonathan M. Poole to its board of directors - marketscreener.com
Acadia Pharmaceuticals Appoints Jonathan M. Poole To Its Board Of Directors - TradingView
ACADIA Stock (-7.1%): EU Regulator Rejects Rett Syndrome Drug Trofinetide - Trefis
Acadia, undaunted by recent EU rejection, seeks CHMP re-examination of Rett syndrome med Daybue - Fierce Pharma
Acadia Faces EU Setback On Trofinetide As Valuation Gap Widens - simplywall.st
Prolium’s $50M Series A raise; COUR Pharma touts liver drug follow-up - Endpoints News
ACADIA Pharmaceuticals Inc. (ACAD) Stock Analysis: Navigating a 38.97% Potential Upside Amid Biotech Challenges - DirectorsTalk Interviews
Acadia receives negative EU opinion for Rett syndrome drug - Investing.com India
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Inside Biotech: Acadia seeks second look from European regulators on trofinetide - Proactive financial news
BofA cuts Acadia Pharmaceuticals stock price target on EU setback By Investing.com - Investing.com Canada
BofA cuts Acadia Pharmaceuticals stock price target on EU setback - Investing.com South Africa
BofA cuts Acadia Pharmaceuticals price target on pipeline review By Investing.com - Investing.com India
BofA cuts Acadia Pharmaceuticals price target on pipeline review - Investing.com
ACADIA Pharmaceuticals Targets $1.7B Sales by 2028, Teases Key Phase 2 Data in 2025 - MarketBeat
ACADIA Pharmaceuticals recently announced that, following a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) regarding its Rett syndrome treatment Trofinetide, the company plans to formall - Bitget
Acadia receives negative EU opinion for Rett syndrome drug By Investing.com - Investing.com UK
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome - Yahoo Finance
Wolfe Research Notes Conviction-Driven Opportunities in ACADIA Pharmaceuticals Inc.'s (ACAD) Therapeutic Domains - Bitget
Wolfe Research Notes Conviction-Driven Opportunities in ACADIA Pharmaceuticals Inc.’s (ACAD) Therapeutic Domains - Yahoo Finance
Acadia Pharmaceuticals' Rett Syndrome Medication Less Likely to Receive EU Approval, RBC Says - marketscreener.com
HC Wainwright Brokers Decrease Earnings Estimates for ACAD - MarketBeat
ACADIA Pharmaceuticals Charts Growth Path After Record Year - TipRanks
Erste Asset Management GmbH Lowers Stock Position in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Acadia Pharmaceuticals (ACAD) Margin Expansion To 36.5% Tests Bearish Earnings Narratives - Sahm
Acadia Pharmaceuticals: Undervalued Despite Robust Revenues From Approved Drugs, With Pipeline Kicker - Seeking Alpha
Vanguard Group Inc. Reduces Stock Position in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Lawsuit - GuruFocus
ACADIA Pharmaceuticals' Rett Syndrome Drug Faces EMA Setback - marketscreener.com
What is HC Wainwright's Estimate for ACAD Q3 Earnings? - MarketBeat
State of New Jersey Common Pension Fund D Purchases Shares of 85,821 ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACAD Stock Price, Forecast & Analysis | ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ChartMill
Decoding ACADIA Pharmaceuticals Inc (ACAD): A Strategic SWOT Ins - GuruFocus
Baker Bros. in ACADIA (NASDAQ: ACAD) secure long-term resale rights - Stock Titan
Will ACADIA Pharmaceuticals' (ACAD) 2025 Earnings Beat and 2026 Guidance Shift Its Growth Narrative? - Yahoo Finance
TD Cowen Raises Price Target for ACADIA Pharmaceuticals (ACAD) | - GuruFocus
TD Cowen Issues Positive Forecast for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price - MarketBeat
Jefferies raises Acadia Pharmaceuticals stock price target on guidance By Investing.com - Investing.com South Africa
ACAD: RBC Capital Lowers Price Target While Maintaining Outperfo - GuruFocus
ACAD Q4 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth - Finviz
Royal Bank Of Canada Lowers ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $30.00 - MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Raised to $35.00 - MarketBeat
ACAD: Citizens Analyst Raises Price Target to $35.00, Maintains Market Outperform Rating | ACAD Stock News - GuruFocus
ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Lowered to $24.00 at Stifel Nicolaus - MarketBeat
Jefferies raises Acadia Pharmaceuticals stock price target on guidance - Investing.com Nigeria
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):